当前位置:
X-MOL 学术
›
Eur. J. Med. Chem.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy
European Journal of Medicinal Chemistry ( IF 6.0 ) Pub Date : 2018-09-03 , DOI: 10.1016/j.ejmech.2018.08.100 Guillaume Compain , Nassima Oumata , Jonathan Clarhaut , Elodie Péraudeau , Brigitte Renoux , Hervé Galons , Sébastien Papot
中文翻译:
β-葡萄糖醛酸苷酸酶反应性白蛋白结合前药,用于潜在的基于选择性激酶抑制剂的癌症化疗
更新日期:2018-09-03
European Journal of Medicinal Chemistry ( IF 6.0 ) Pub Date : 2018-09-03 , DOI: 10.1016/j.ejmech.2018.08.100 Guillaume Compain , Nassima Oumata , Jonathan Clarhaut , Elodie Péraudeau , Brigitte Renoux , Hervé Galons , Sébastien Papot
![]() |
We report on the synthesis and in vitro biological evaluations of a nanomolar protein kinase inhibitor (PKI) and its β-glucuronidase-responsive albumin-binding prodrug. The highly potent PKI is 400–3400 times more cytotoxic than the well-known PKI Roscovitine. The prodrug is able to bind covalently to human serum albumin through Michael addition and release the cytotoxic PKI in the presence of β-glucuronidase, an enzyme over-expressed in the microenvironment of solid tumours.
中文翻译:
![](https://scdn.x-mol.com/jcss/images/paperTranslation.png)
β-葡萄糖醛酸苷酸酶反应性白蛋白结合前药,用于潜在的基于选择性激酶抑制剂的癌症化疗
我们报告了纳摩尔蛋白激酶抑制剂(PKI)及其β-葡萄糖醛酸苷酶反应性白蛋白结合前药的合成和体外生物学评价。高效的PKI的细胞毒性是著名的PKI Roscovitine的400-3400倍。该前药能够通过迈克尔加成与人血清白蛋白共价结合,并在存在于实体瘤微环境中过表达的β-葡萄糖醛酸苷酶的情况下释放细胞毒性PKI。